References
- Campanati A, Neri P, Giuliodori K, et al. Psoriasis beyond the skin surface: a pilot study on the ocular involvement. Int Ophthalmol. 2015;35:331–340.
- Waller J, Wu J, Murase J, et al. Chronically painful right thumb with pustules and onycholysis. Diagnosis: Acrodermatitis continua of Hallopeau. Clin Exp Dermatol. 2007;32:619–620.
- Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62:655–662.
- Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–864.
- Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3:5–29.
- Patel NU, Vera NC, Shealy ER, et al. A review of the use of secukinumab for psoriatic arthritis. Rheumatol Ther. 2017;4:233–246.
- Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy. 2017;9:229–238.
- Burkett PR, Kuchroo VK. IL-17 blockade in psoriasis. Cell. 2016;167:1669.
- Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014; 28:1670–1675.
- Reich K, Sullivan J, Arenberger P, et al. Secukinumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: 16 week results from the TRANSFIGURE study. 23rd World Congress of Dermatology. Vancouver, Canada. 11 June 2015.
- Stinco G, Errichetti E. Erythrodermic psoriasis: current and future role of biologicals. BioDrugs. 2015;29:91–101.
- Galluzzo M, D’Adamio S, Bianchi L, et al. Brodalumab for the treatment of psoriasis. Exp Rev Clin Immunol. 2016;13:1255–1271.
- Saeki H, Nakagawa H, Nakajo K. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–362.
- Dogra S, Bishnoi A, Narang T, et al. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018;31:e12611.
- Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, et al. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018;31:e12607.
- Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178:1439–1440.
- Mugheddu C, Atzori L, Lappi A, et al. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31:e420–e421.
- Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep. 2017;3:215–218.
- Muggli D, Maul JT, Anzengruber F, et al. Secukinumab for Acrodermatitis Continua of Hallopeau. JAMA Dermatol. 2017;153:336–337.
- Bohner A, Roenneberg S, Eyerich K, et al. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2016;152:482–484.
- Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–1017.
- Burder-Teh E, Murphy R. Psoriasis and uveitis – should we be asking about eye symptoms? Br J Dermatol. 2014;170:756–757.
- Her Y, Lim JW, Han SH. Dry eye and tear film functions in patients with psoriasis. Jpn J Ophthalmol. 2013;57:341–346.